FY2025 EPS Estimate for Core Laboratories Lowered by Analyst

Core Laboratories Inc. (NYSE:CLB - Free Report) - Zacks Research lowered their FY2025 earnings estimates for shares of Core Laboratories in a note issued to investors on Monday, June 16th. Zacks Research analyst R. Department now anticipates that the oil and gas company will post earnings per share of $0.70 for the year, down from their previous estimate of $0.71. The consensus estimate for Core Laboratories' current full-year earnings is $0.96 per share. Zacks Research also issued estimates for Core Laboratories' Q3 2026 earnings at $0.19 EPS, Q4 2026 earnings at $0.27 EPS, FY2026 earnings at $0.83 EPS and Q1 2027 earnings at $0.21 EPS.

CLB has been the subject of several other research reports. Stifel Nicolaus decreased their price objective on Core Laboratories from $19.00 to $15.00 and set a "hold" rating for the company in a report on Tuesday, April 15th. Citigroup cut their price objective on Core Laboratories from $16.00 to $13.00 and set a "neutral" rating for the company in a report on Tuesday, May 13th. Finally, Wall Street Zen downgraded Core Laboratories from a "hold" rating to a "sell" rating in a research report on Friday, April 25th. Two research analysts have rated the stock with a sell rating and three have issued a hold rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Hold" and an average price target of $15.00.

Core Laboratories Stock Performance

Shares of CLB stock opened at $12.08 on Tuesday. The company has a market cap of $566.49 million, a price-to-earnings ratio of 18.31, a price-to-earnings-growth ratio of 0.99 and a beta of 1.40. Core Laboratories has a 52 week low of $10.14 and a 52 week high of $25.13. The company has a quick ratio of 1.71, a current ratio of 2.32 and a debt-to-equity ratio of 0.49. The firm has a 50 day moving average of $11.74 and a 200-day moving average of $15.12.

Core Laboratories (NYSE:CLB - Get Free Report) last released its earnings results on Wednesday, April 23rd. The oil and gas company reported $0.14 earnings per share for the quarter, missing the consensus estimate of $0.15 by ($0.01). Core Laboratories had a net margin of 5.99% and a return on equity of 16.24%. The firm had revenue of $123.59 million during the quarter, compared to the consensus estimate of $125.09 million. During the same period in the prior year, the business posted $0.19 earnings per share. Core Laboratories's quarterly revenue was down 4.7% compared to the same quarter last year.

Core Laboratories Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Tuesday, May 27th. Shareholders of record on Monday, May 5th were paid a dividend of $0.01 per share. The ex-dividend date was Monday, May 5th. This represents a $0.04 dividend on an annualized basis and a dividend yield of 0.33%. Core Laboratories's dividend payout ratio is currently 6.78%.

Institutional Investors Weigh In On Core Laboratories

A number of large investors have recently made changes to their positions in CLB. Assetmark Inc. purchased a new position in shares of Core Laboratories during the 4th quarter valued at about $26,000. Smartleaf Asset Management LLC raised its holdings in shares of Core Laboratories by 173.8% during the 4th quarter. Smartleaf Asset Management LLC now owns 2,037 shares of the oil and gas company's stock worth $35,000 after acquiring an additional 1,293 shares in the last quarter. AlphaQuest LLC raised its holdings in shares of Core Laboratories by 265,800.0% during the 1st quarter. AlphaQuest LLC now owns 2,659 shares of the oil and gas company's stock worth $40,000 after acquiring an additional 2,658 shares in the last quarter. Tower Research Capital LLC TRC increased its position in shares of Core Laboratories by 843.7% during the 4th quarter. Tower Research Capital LLC TRC now owns 3,284 shares of the oil and gas company's stock valued at $57,000 after purchasing an additional 2,936 shares during the last quarter. Finally, BNP Paribas Financial Markets bought a new position in shares of Core Laboratories during the 4th quarter valued at approximately $123,000. 97.81% of the stock is currently owned by institutional investors.

Core Laboratories Company Profile

Core Laboratories Inc provides reservoir description and production enhancement services and products to the oil and gas industry in the United States, and internationally. It operates through Reservoir Description and Production Enhancement segments. The Reservoir Description segment includes the characterization of petroleum reservoir rock and reservoir fluid samples to enhance production and improve recovery of crude oil and gas from its clients' reservoirs.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.